Disulfidptosis belongs to the growing family of programmed cell death modalities, which already includes apoptosis, necroptosis, pyroptosis, ferroptosis and cuproptosis. What sets it apart is its peculiar trigger and its equally peculiar execution mechanism. Rather than being launched by genetic damage, immune signaling or lipid peroxidation, disulfidptosis arises when a cancer cell suffers a catastrophic metabolic and redox imbalance, one that culminates in the irreversible collapse of the actin cytoskeleton, the internal scaffold that gives the cell its shape and motility. In the simplest terms, the cell’s skeleton literally disintegrates under the strain of accumulated disulfide bonds, and the cell dies.

At the heart of the process lies what the authors describe as the SLC7A11-cystine-NADPH-actin axis. SLC7A11, also known as xCT, is a cystine/glutamate antiporter that many cancer cells upregulate to import cystine, the oxidized dimer of cysteine, which they then reduce to cysteine for the synthesis of glutathione and other antioxidant molecules. This import strategy works well for tumor cells as long as they have abundant glucose, because glucose feeds the pentose phosphate pathway, which generates NADPH, the reducing power needed to convert incoming cystine back into cysteine. The transporter, in other words, is a double-edged sword: it equips cancer cells to withstand oxidative stress, but it creates a hidden dependency on a continuous supply of NADPH.

The vulnerability is exposed when glucose runs out. Under glucose starvation, NADPH production collapses, and the cystine that continues to flood into the cell through SLC7A11 can no longer be reduced. Abnormal levels of intracellular cystine and other disulfide molecules accumulate, and aberrant disulfide bonds begin to form between cysteine residues on a broad range of proteins. Previous work by Liu and colleagues, published in Nature Cell Biology in 2023, demonstrated that the actin cytoskeleton is particularly susceptible to this disulfide stress. When excessive disulfide bonding disrupts actin networks, the cytoskeleton collapses, cells detach from their surroundings, shrink and die. This actin-centered death is the defining hallmark of disulfidptosis.

The review also emphasizes why certain cancer cells are unusually susceptible to this death route. Tumors are metabolically rewired cells, and many of them, including those with high SLC7A11 expression, exist in a state the authors call a fragile redox equilibrium, balancing heavy cystine import against tight NADPH budgets. Notably, cells that have evolved resistance to apoptosis or to ferroptosis, the iron-dependent lipid peroxidation death, often show heightened vulnerability to disulfidptosis, suggesting that this pathway could be exploited against tumors that have outmaneuvered conventional therapies. This synthetic-lethal logic, where a second stress is applied to cells already carrying a metabolic liability, underlies much of the enthusiasm surrounding the field.

Regulation of disulfidptosis is a multi-layered affair, spanning metabolic, redox and signaling networks. On the metabolic side, glucose uptake through transporters such as GLUT1 and GLUT3, glycolytic flux, and activity of the pentose phosphate pathway enzymes glucose-6-phosphate dehydrogenase (G6PD) and 6-phosphogluconate dehydrogenase all determine how much NADPH a cell can muster. The review highlights that cancer cells can draw NADPH from alternative sources, including lactate and glutamine metabolism, when glucose is scarce, which complicates therapeutic strategies based purely on glucose deprivation. On the redox side, the glutathione system, comprising glutathione, glutathione peroxidases and glutathione reductase, and the thioredoxin system, comprising thioredoxin, thioredoxin reductase and related proteins such as TRP14, act as buffers against disulfide stress. Inhibiting thioredoxin reductase 1, for example, has been shown to sensitize glucose-starved glioblastoma cells to disulfidptosis, as reported by Tang and colleagues in Cell Death and Differentiation in 2025.

Several key signaling pathways tune this machinery. The Keap1-Nrf2 pathway, the master sensor of oxidative and electrophilic stress, regulates the expression of SLC7A11 and a suite of antioxidant genes, and its frequent activation in tumors, through Keap1 mutations or NRF2 stabilization, can either protect cells from disulfide stress or, paradoxically, load them with more cystine import capacity that becomes lethal when energy fails. The AMPK pathway, activated under energy stress through LKB1 and other sensors, helps cells conserve NADPH and survive glucose starvation; cells with LKB1 mutations, such as a subset of non-small cell lung cancers, are consequently more likely to die by disulfidptosis when deprived of glucose. The tumor suppressor p53 adds another layer of complexity, shaping glucose metabolism and redox gene expression in ways that can either sensitize or protect cells depending on context.

The review also details the cytoskeletal components that serve as executioners of the process. Rac1, a small GTPase that governs actin polymerization, activates the WAVE regulatory complex, which includes NCKAP1 and the Arp2/3-activating machinery that drives branched actin network formation. Disulfide stress-induced aberrant bonding among actin and its interacting proteins cripples these structures, and studies have shown that manipulating Rac1-WAVE signaling alters sensitivity to disulfidptosis. Because many of these same proteins also drive cancer cell migration, invasion and metastasis, the actin cytoskeleton represents a doubly attractive target: disrupting it kills vulnerable tumor cells and simultaneously undermines their ability to spread.

Importantly, the authors caution that the story is not uniformly favorable. Functional polarity reversal of core regulatory molecules, in which a factor that normally promotes disulfidptosis in one context protects against it in another, and the profound heterogeneity of tumors can both blunt therapeutic efficacy. Some tumors with low SLC7A11 expression may be resistant, while others compensate through alternative NADPH-generating routes. This heterogeneity is one of the principal bottlenecks the field must overcome, alongside a shortage of highly specific pharmacological tools to induce or inhibit disulfidptosis selectively.

Despite these challenges, early translational efforts are encouraging. Researchers have developed nanoinducers, including copper-based nanoparticles and FTO-targeting nanodrugs, that promote disulfidptosis while simultaneously remodeling the immunosuppressive tumor microenvironment, thereby boosting immunotherapy. Sonodynamic nanoparticles carrying GLUT1 inhibitors and cystine-containing polymers have been tested in bladder cancer models. Combination strategies pairing disulfidptosis induction with ferroptosis, cuproptosis or pyroptosis, or with agents that inhibit DNA repair and force cell cycle arrest, are being explored to enhance tumor killing. The review argues that the selectivity of disulfidptosis for metabolically vulnerable cancer cells, which spares normal cells that lack the same cystine-import dependence, offers a route toward therapies with a wider therapeutic window than conventional cytotoxic chemotherapy.

Looking forward, the authors call for precise molecular classification systems that identify which tumors carry the disulfidptosis-susceptible phenotype, development of targeted drugs against the SLC7A11-NADPH-actin axis, and exploration of synergistic strategies combining metabolic interventions with immunotherapy. If those goals can be met, disulfidptosis may move from a laboratory curiosity to a genuine clinical option, giving oncologists a way to exploit the very metabolic addictions that cancer cells rely on for survival. For now, the field stands at an inflection point, with the fundamental biology largely mapped and the first-generation tools beginning to emerge, and the coming years will determine whether the actin cytoskeleton, that ancient structural scaffold of the cell, becomes the next great target in cancer medicine.

EZH2, short for enhancer of zeste homolog 2, is best known as a catalytic component of the Polycomb Repressive Complex 2, or PRC2. In that classical role, EZH2 adds methyl groups to histone H3 at lysine 27, a chemical modification commonly designated H3K27me3. Histones are proteins around which DNA is wrapped, and chemical marks on them can influence whether nearby genes are accessible for transcription. EZH2 is often overexpressed or abnormally activated in cancers, where it has generally been associated with the repression of genes that restrain cell proliferation or promote differentiation. Patients whose tumours contain high levels of EZH2 frequently have poorer clinical outcomes. Yet the exact ways in which excess EZH2 strengthens tumour-forming ability have not been fully explained. The new work expands that picture by showing that EZH2 can participate in a noncanonical, or nontraditional, function: rather than acting only as a chromatin-modifying repressor, it helps stimulate a gene-expression programme connected to lipid metabolism.

The key partner in this process is SREBP2, or sterol regulatory element-binding protein 2. SREBP2 is a transcription factor that monitors and controls cellular cholesterol production. When cells require more cholesterol, SREBP2 can become activated and move into the nucleus, where it binds regulatory DNA sequences near genes involved in cholesterol uptake and synthesis. Among its major targets are genes in the mevalonate pathway, a series of enzymatic reactions that converts acetyl-CoA into cholesterol and other sterol-related products. Cholesterol is not merely a structural component of cell membranes. It also contributes to membrane organization, intracellular signalling and the production of steroid-related molecules. Rapidly dividing cancer cells can place unusually high demands on these systems as they build new membranes and adapt to stressful environments. The study indicates that EZH2 and SREBP2 cooperate to drive high expression of mevalonate-pathway genes, effectively linking an epigenetic cancer-associated protein to a metabolic switch that can increase the supply of cholesterol.

The researchers describe a direct molecular connection between the two proteins and the transcriptional machinery that activates cancer-related genes. According to the study, transcriptional activation domains within EZH2 and SREBP2 bind directly to p300, a well-known coactivator that helps turn genes on. p300 can modify histones and other proteins through acetylation, a process that often promotes a more transcriptionally permissive chromatin environment. In this model, the EZH2–SREBP2 partnership is not simply bringing two regulatory proteins into proximity; it is also recruiting a coactivator capable of strengthening gene activation. The result is a functional complex that supports expression of genes in the mevalonate pathway and activates proto-oncogene programmes. Proto-oncogenes normally contribute to controlled growth and survival, but when inappropriately activated they can promote malignant transformation. This mechanism provides a possible explanation for how high EZH2 levels can support cancer even when its tumour-promoting activity does not fit the classic PRC2-mediated model of gene repression.

The implications are especially striking because cholesterol metabolism has often been viewed as a supporting feature of cancer biology rather than as a central output of EZH2 activity. Tumours rewire metabolism to obtain energy, construct cellular components and survive conditions such as nutrient limitation or low oxygen. Increased cholesterol synthesis may help supply the membrane material required for proliferation, while mevalonate-pathway intermediates can influence signalling and protein modification. The study’s findings place EZH2 near the top of that metabolic control system, where it may help SREBP2 maintain the expression of multiple biosynthetic genes at once. This is different from blocking a single enzyme downstream in the pathway. A regulatory partnership that controls a broad gene set could, in principle, produce a larger effect on tumour biology—but it could also create challenges, because cholesterol production is essential to normal cells. The research therefore points to a vulnerability, not yet a finished treatment strategy, and further work would be needed to determine how selectively the pathway can be disrupted in cancer.

To test whether this noncanonical function could be targeted, the researchers used proteolysis-targeting chimeras, widely known as PROTACs. These are engineered molecules designed to bring a target protein into contact with an E3 ubiquitin ligase, part of the cell’s protein-disposal system. Once recruited, the target can be tagged with ubiquitin and sent to the proteasome, a large molecular machine that breaks down proteins. Unlike conventional inhibitors, which generally occupy a functional pocket and block activity, PROTACs can remove a protein from the cell and may continue acting catalytically as long as the degradation machinery remains available. In the study, independent EZH2-targeting PROTACs degraded EZH2 and, notably, also reduced SREBP2. This dual effect suppressed SREBP2-associated gene-expression programmes, including those linked to cholesterol biosynthesis, and inhibited tumour growth. The result suggests that eliminating EZH2 may dismantle the regulatory partnership more effectively than simply blocking one of its biochemical activities.

The observation that EZH2-targeting PROTACs affect both proteins is central to the study’s therapeutic significance. If EZH2 supports tumour growth through several distinct functions, an agent that removes the protein could potentially block more than a single catalytic activity. Degradation of EZH2 may weaken its association with SREBP2, reduce the availability of the coactivator p300 at relevant genes and collapse the transcriptional programme that sustains the mevalonate pathway. The accompanying loss of SREBP2 would further limit the cell’s ability to activate cholesterol-biosynthesis genes. Together, these effects could explain why the PROTAC strategy inhibited tumour growth in the researchers’ experiments. However, the findings do not establish that such compounds are ready for clinical use, nor do they show that every cancer with high EZH2 depends on the same mechanism. Tumours are genetically and metabolically diverse, and cholesterol production is also vital in healthy tissues. The future challenge will be identifying cancers most reliant on the EZH2–SREBP2 axis while minimizing damage to normal metabolism.

The work ultimately shifts the way scientists may think about EZH2 in cancer. Rather than treating the protein solely as an epigenetic repressor that silences protective genes, the study presents it as a versatile regulator capable of joining a transcriptional complex that actively promotes metabolic and oncogenic programmes. Its partnership with SREBP2 creates a bridge between chromatin biology, gene activation and lipid metabolism, revealing how a cancer-associated protein can influence the supply of molecules needed for tumour expansion. The findings also illustrate why protein degradation strategies are attracting attention: destroying a regulatory protein can expose vulnerabilities created by its interactions, not just those associated with its best-known enzymatic function. By identifying cholesterol biosynthesis as a downstream output of EZH2–SREBP2 cooperation, the researchers offer a new framework for understanding tumour metabolism and a potential route for therapeutic development. The axis is not yet a proven universal weakness, but it may represent a molecular Achilles’ heel in cancers that depend on elevated EZH2 activity and SREBP2-driven cholesterol production.

Decitabine, an established chemotherapy used for bone marrow disorders and acute myeloid leukemia, works by incorporating into the genome and triggering cell death. However, the researchers explain that DCTPP1 recognizes chemically modified pieces of DNA generated during this process and degrades them, reducing decitabine’s anticancer potency. In prostate cancer cells, where drug responses can become weaker, this degradation may contribute to incomplete therapeutic effects.

To identify ways to disable DCTPP1, the team began with structural biology and chemical screening. They screened 10,000 compounds to find candidates that inhibit DCTPP1 activity. Three distinct chemical classes emerged, suggesting that the protein can be blocked through specific binding interactions.

The researchers then used X-ray crystallography to determine atomic-resolution structures of DCTPP1 bound to these inhibitors. This approach revealed that each inhibitor class occupies a particular nucleotide-binding pocket. With binding modes clarified at the atomic level, the team combined the DCTPP1 inhibitors with decitabine in living prostate cancer cell cultures.

Their experiments indicate that adding DCTPP1 inhibitors boosts decitabine’s effectiveness at killing prostate cancer cells. The findings support the idea that stopping DCTPP1 prevents degradation of decitabine-related DNA modifications, allowing the chemotherapy’s genome-integrating mechanism to proceed more fully.

The study was published June 15 in Proceedings of the National Academy of Sciences as part of NIH-funded research. The authors emphasize that future work will test whether these inhibitor scaffolds can be optimized to further increase potency and potentially extend benefits to additional cancer types beyond prostate cancer.

For patients facing castration-resistant prostate cancer, a form that can metastasize and has a low five-year survival rate, improved drug combinations could be clinically valuable. By repurposing and enhancing an existing therapy rather than developing entirely new drugs, the approach offers a strategic path toward more durable responses.

Funding included support from the National Cancer Institute and additional foundations, reflecting the multi-institutional effort behind the program.

Subject of Research: DCTPP1 protein inhibition to enhance decitabine activity in prostate cancer
Article Title: Newly Identified Inhibitors May Boost Chemotherapy Drug’s Ability to Fight Treatment-Resistant Cancers
News Publication Date: June 15
Web References: https://www.pnas.org/doi/full/10.1073/pnas.2534029123
References: Proceedings of the National Academy of Sciences (June 15)
Image Credits: James Berger
Keywords: DCTPP1; decitabine; prostate cancer; inhibitors; X-ray crystallography; nucleotide-binding pocket; DNA damage; genome integrity; chemotherapy sensitization; treatment resistance

Metastasis, the process through which cancer cells spread from a primary tumor site to distant organs, remains the foremost cause of cancer-related mortality. Unlike primary tumors, metastatic cancer cells evade most conventional treatments, often leading to poor prognoses and limited therapeutic options. Triple-negative breast cancer (TNBC), an aggressive subtype lacking estrogen, progesterone, and HER2 receptors, disproportionately affects younger women and comprises roughly 10 to 15% of breast cancers. TNBC’s high metastatic potential and resistance to standard hormone therapies exacerbate the urgency for novel, targeted treatments.

Kolonin’s team zeroed in on the peptide BLMP6 due to its remarkable ability to bind specifically to metastatic breast cancer cells. Utilizing advanced molecular imaging techniques, the researchers conjugated BLMP6 with a fluorescent dye, enabling them to visualize the peptide’s selective accumulation within metastatic lesions in vivo. In mouse models grafted with human triple-negative breast tumors, BLMP6’s precision allowed unprecedented real-time tracking of metastatic dissemination.

Building on these imaging breakthroughs, the researchers further enhanced BLMP6’s therapeutic potential by chemically linking it to monomethyl auristatin E (MMAE), an FDA-approved cytotoxic payload. This peptide-drug conjugate demonstrated significant efficacy in preclinical trials, dramatically suppressing metastatic tumor growth and extending survival in experimental mice. This specificity reduces off-target toxicity typically associated with conventional chemotherapy, which indiscriminately affects both healthy and malignant cells.

A critical component of this innovation lies in BLMP6’s target: fibulin-4, an extracellular matrix protein found in elevated concentrations within metastatic breast cancer tissues. Through state-of-the-art artificial intelligence modeling and structural bioinformatics, the research team elucidated the molecular interaction mechanism underpinning BLMP6 and fibulin-4 binding, confirming that fibulin-4 acts as a beacon on metastatic tumor cells.

Further translational research demonstrated that BLMP6’s selective binding to fibulin-4 is conserved in human breast cancer tissues. By screening arrays of patient-derived breast cancer samples representing various stages and invasiveness, the researchers validated that BLMP6 preferentially associates with aggressive, invasive breast cancers while showing minimal affinity for noninvasive or normal breast tissue. This finding underscores BLMP6’s potential as both a diagnostic imaging agent and a therapeutic vector to selectively target deadly cancer cells.

The implications of targeting fibulin-4 are profound. This protein, whose expression is upregulated in metastatic environments, may serve as a novel biomarker indicative of metastatic progression. Therapeutic strategies leveraging such specific molecular markers could revolutionize personalized oncology by enabling earlier detection of metastasis and delivering targeted treatments that mitigate systemic toxicity.

Kolonin emphasized the dual utility of BLMP6-based technology: “There is efficacy of both the BLMP6-drug conjugate and BLMP6-based imaging probes useful for metastasis detection that we demonstrated in preclinical cancer models. This is really exciting.” This dual functionality paves the way for integrated diagnostic and therapeutic (“theranostic”) platforms that can monitor disease spread while simultaneously administering targeted therapy.

The research carried out by Kolonin’s team extends beyond peptide discovery. It integrates advanced AI-driven molecular modeling with rigorous experimental validation across in vivo models and human tissue samples, exemplifying a multidisciplinary approach that spans molecular biology, computational science, and clinical oncology.

The study’s findings were published in the prestigious journal Molecular Therapy Oncology, highlighting a new frontier in biotechnology-driven cancer therapeutics. This approach, combining computational prediction with biological validation to identify novel peptide targets, represents a paradigm shift in addressing metastatic breast cancer and potentially other malignancies.

Looking ahead, this technology holds promise for clinical translation. The selective targeting mechanism could allow oncologists to more accurately stage metastasis and tailor treatments accordingly. Moreover, the modular nature of peptide-drug conjugates like BLMP6-MMAE facilitates adaptation against diverse cancer targets, advancing precision medicine goals.

Beyond breast cancer, the methodology sets a precedent for exploiting extracellular matrix components like fibulin-4 as therapeutic targets. This shifts focus from intracellular signaling pathways to the tumor microenvironment, opening additional avenues to disrupt metastatic niches and halt cancer progression at critical junctures.

In conclusion, the discovery of BLMP6’s specificity for metastatic breast cancer cells via fibulin-4 binding marks a significant milestone in overcoming the challenges of metastatic disease. Leveraging peptide-based probes combined with cytotoxic agents offers a promising strategy for targeted cancer therapy, potentially transforming clinical outcomes for patients suffering from aggressive breast cancers with a propensity to metastasize.

Subject of Research: Targeting metastatic triple-negative breast cancer cells through peptide-based imaging probes and therapeutics.

Article Title: Fibulin-4 expressed in metastatic breast cancer is a target of peptide-based imaging probes and experimental therapeutics

Web References: https://www.cell.com/molecular-therapy-family/oncology/fulltext/S2950-3299(26)00083-4

Image Credits: Photo by UTHealth Houston

Keywords: metastatic breast cancer, triple-negative breast cancer, peptide-based therapeutics, BLMP6, fibulin-4, molecular imaging, peptide-drug conjugate, monomethyl auristatin E, artificial intelligence, cancer metastasis, targeted therapy, theranostics

G3-MB presents a formidable challenge in pediatric oncology due to its poor prognosis and resistance to current treatment modalities. A key driver of this malignancy is the overexpression of MYC, an oncogene that orchestrates cellular processes promoting rapid proliferation and tumor aggressiveness. Unlike typical gene amplifications residing within chromosomes, MYC is often amplified on extrachromosomal DNA (ecDNA) in these tumors. EcDNA consists of circular DNA elements detached from chromosomes, which can replicate independently, resulting in variable gene copy numbers. This dynamic genomic structure confers a formidable adaptability to cancer cells, enabling sustained high-level MYC expression that drives malignant progression.

The St. Jude team employed a combination of cutting-edge genomic techniques, including three-dimensional genome mapping, chromatin profiling, and CRISPR-based functional screens, to interrogate the regulatory landscape governing MYC expression on ecDNA. Their investigations identified a crucial enhancer element within the ecDNA, termed ecMYC E1, that exerts strong control over MYC transcription. Enhancers are segments of DNA that facilitate gene activation by physically interacting with promoter regions, acting as molecular switches that modulate gene output. This discovery revealed a previously unrecognized regulatory circuit uniquely embedded within the extrachromosomal genetic architecture of G3-MB tumors.

What makes this finding particularly significant is that ecMYC E1 is highly active and exclusive to tumor cells harboring extrachromosomal MYC amplification, rendering it a promising therapeutic target. Functional interrogation using brain tumor organoid models—three-dimensional cultures that recapitulate the histological and molecular features of patient tumors—demonstrated that silencing this enhancer markedly reduced MYC transcription. This reduction in oncogenic expression translates to a potential strategy to curb tumor growth while sparing normal tissues. These organoid models retain the genetic heterogeneity of the original tumors, offering an unparalleled platform to study ecDNA-mediated oncogene regulation in a physiologically relevant context.

Despite the promising results, the researchers discovered a remarkable adaptive mechanism employed by cancer cells in response to ecMYC E1 inhibition. Initially, suppressing the enhancer led to diminished MYC levels; however, tumor cells counteracted this effect by increasing the copy number of MYC-carrying ecDNA. This ecDNA amplification restored oncogene expression, revealing an intrinsic resilience powered by the unique replication capability of extrachromosomal elements. Intriguingly, this adaptive response was absent in tumors where MYC amplification is integrated within chromosomes, underscoring the distinct biology of ecDNA-driven cancers.

To address this obstacle, the research team proposes a combinatorial therapeutic strategy. Enhancer silencing could be paired with agents that hinder the increase in ecDNA copy number, such as checkpoint kinase 1 (CHK1) inhibitors. CHK1 plays a key role in DNA replication and cell cycle regulation, and its inhibition could prevent the compensatory ecDNA amplification, thereby enhancing treatment efficacy. This dual-pronged approach targets both the regulatory circuitry and the resilient genomic architecture, potentially overcoming tumor resistance mechanisms.

The implications of these findings extend beyond medulloblastoma. Approximately 28% of cancers feature oncogene amplification on ecDNA, suggesting a broader applicability for therapies targeting ecDNA-associated enhancers. However, MYC’s intractable structure and central oncogenic role have historically stymied efforts to develop direct inhibitors. This study marks a conceptual shift, focusing on the regulatory elements that govern MYC expression rather than the protein itself. By exploiting the unique vulnerabilities of ecDNA in tumor cells, new treatment avenues may emerge for a spectrum of high-risk malignancies driven by MYC.

Key to this research was the integration of multi-dimensional genomic technologies with innovative functional assays. The 3D genome mapping techniques allowed visualization of physical interactions between enhancers and promoters within the spatial organization of the nucleus. Chromatin profiling illuminated the epigenetic landscape defining active regulatory elements, while CRISPR-based screens enabled functional validation by selectively silencing candidate enhancers. Together, these methodologies provided a comprehensive understanding of how ecDNA confers regulatory autonomy to MYC, a phenomenon absent in chromosomally encoded genes.

The study was spearheaded by Dr. Martine Roussel, a prominent figure in tumor cell biology at St. Jude, with doctoral candidate Jake Friske playing a pivotal role in executing and interpreting the experimental findings. The collaboration incorporated expertise across genetics, molecular biology, and bioinformatics, reflecting the multidisciplinary nature of contemporary cancer research. The work was supported by grants from the National Cancer Institute, American Cancer Society, Broad Institute’s Pediatric Cancer Dependencies Accelerator, and other partners, highlighting the critical need for investment in pediatric cancer science.

Moreover, the study’s use of brain tumor organoids represents a significant advance in modeling tumor biology. These organoid systems simulate tumor microenvironments and preserve genetic diversity, providing a more faithful representation of tumor behavior than traditional cell lines. This fidelity enabled detailed studies of enhancer function and resistance mechanisms in a controlled but biologically relevant setting. The findings underscore the value of such models in preclinical research and drug development pipelines.

This research not only broadens our understanding of MYC regulation but also exemplifies the adaptive complexity of cancer genomes. EcDNA offers tumors a genomic plasticity that facilitates rapid evolution under therapeutic pressure. By targeting both the regulatory elements and replication mechanisms of ecDNA, future treatments may effectively outmaneuver tumor adaptability, providing hope for improved outcomes in children afflicted with these devastating brain tumors.

In conclusion, the identification of the ecMYC E1 enhancer on extrachromosomal DNA represents a paradigm shift in targeting MYC-driven pediatric medulloblastoma. This enhancer acts as a linchpin in sustaining oncogenic MYC expression, and its inhibition, combined with blockade of ecDNA amplification, holds promise for refined, less toxic therapeutic strategies. As the scientific community continues to unravel the complexities of ecDNA biology, the strategies illuminated by this landmark study may pave the way for innovative interventions against some of the most intractable pediatric cancers.

Subject of Research: Regulatory mechanisms of MYC oncogene expression in pediatric Group 3 medulloblastoma and novel therapeutic targets on extrachromosomal DNA.

Article Title: Enhancer provides a potential target for ‘undruggable’ MYC in pediatric medulloblastoma.

News Publication Date: April 22, 2026.

Web References:

• St. Jude Children’s Research Hospital: https://www.stjude.org/
• Article DOI: http://dx.doi.org/10.1158/0008-5472.CAN-25-4691

Image Credits: St. Jude Children’s Research

Keywords: Medulloblastoma, Oncogenes, MYC, Extrachromosomal DNA, ecDNA, Enhancer, Chromatin profiling, CRISPR screening, Pediatric brain tumors, Tumor organoids, Cancer genomics, Therapeutic resistance

Typically, animal cells maintain a diploid state with two sets of chromosomes, one inherited maternally and the other paternally. However, polyploidy emerges when cells either duplicate their genome in preparation for division but fail to undergo cytokinesis, or develop through alternative mechanisms. While polyploidy can serve essential physiological roles—such as enabling liver cells to enlarge and adapt to metabolic demands—it is increasingly recognized as a driver in malignancy, endowing cancer cells with heightened resistance to environmental stresses, therapeutic interventions, and enhanced proliferative capacity.

Led by Professor Wu-Min Deng, the Tulane research team employed Drosophila melanogaster larvae as an experimental model to elucidate the consequences of polyploidy on epithelial cell behavior. Through genetic manipulation, they induced polyploidy within these cells and observed a striking phenotypic transformation. Unlike their diploid counterparts, polyploid cells exhibited pronounced migratory aptitude, actively moving through tissues rather than remaining static. Intriguingly, these polyploid cells also engaged in phagocytosis, engulfing neighboring diploid cells, especially those undergoing apoptosis or otherwise compromised in health.

Mechanistically, the study identifies a critical link between increased chromosome content and augmented protein synthesis. The metabolic burden imposed by excess protein production leads to perturbations within the protein folding and synthesis machinery of the cell, resulting in elevated levels of reactive oxygen species (ROS). The accumulation of ROS activates the Jun N-terminal kinase (JNK) signaling pathway, a well-characterized stress response mechanism in cells. This pathway, once engaged, drives cytoskeletal reorganization and transcriptional changes that collectively potentiate cell motility and phagocytic activity.

Importantly, intervention experiments demonstrated that treating fruit flies with antioxidants effectively suppressed ROS accumulation, dampening JNK pathway activation and consequently reducing the migratory and engulfment capabilities of polyploid cells. Similarly, pharmacological inhibition of JNK signaling elicited comparable effects, underscoring the pivotal role of this pathway in reprogramming epithelial cell behavior in response to polyploidy-induced stress.

Expanding the relevance of these findings beyond model organisms, the researchers investigated human lung cancer cells engineered to undergo polyploidization. Consistent with their in vivo observations in Drosophila, polyploid human cancer cells displayed enhanced motility. When treated with antioxidants or JNK inhibitors, these human cells exhibited markedly reduced migration, confirming that the ROS-JNK axis activated by polyploidy is conserved across species and critical in modulating cancer cell dynamics.

This convergence of stress signaling and altered cell phenotype sheds light on why polyploid cancer cells accumulate in particularly aggressive, treatment-resistant tumors. By co-opting the stress response machinery, these cells gain units of advantage: they can invade adjacent tissues by migrating and simultaneously eliminate weaker competing cells through phagocytosis, effectively sculpting the tumor microenvironment to favor their survival and expansion.

The discovery that polyploidy-induced ROS production and JNK activation can be pharmacologically modulated suggests a promising therapeutic avenue. Drugs targeting elements of this stress-sensing axis could potentially inhibit the aggressive traits of polyploid cancer cells, limiting invasion and metastasis without affecting diploid cells that constitute normal tissue architecture. Such selectivity is crucial to minimizing side effects during cancer treatment.

Moreover, the study highlights the intricate interplay between genome duplication, metabolic stress, and cellular signaling pathways. It emphasizes the need for a deeper understanding of how subtle alterations in chromosome number can ripple through molecular networks to induce profound changes in cell behavior. This paradigm shift in cancer biology challenges the classical view of polyploidy solely as a consequence of genomic instability, positioning it instead as an active driver of tumor evolution and malignancy.

The research conducted by Deng et al. also opens new questions about the evolutionary advantages of polyploidy in normal physiology versus pathology. While polyploidy facilitates tissue growth and regeneration under controlled settings, its aberrant manifestation in cancer alters tissue homeostasis detrimentally. Deciphering the molecular switches that discriminate between beneficial and harmful polyploidy outcomes may aid in designing targeted interventions.

In conclusion, this landmark study elucidates how polyploid cells harness oxidative stress and the JNK signaling pathway to gain migratory and phagocytic capabilities, thereby contributing to the invasive potential of tumors. By bridging insights from fruit fly models to human cancer cells, the findings establish a conserved mechanistic framework with significant implications for cancer therapy. Targeting the stress-induced motility program of polyploid cells holds promise for developing strategies to combat aggressive cancers that currently elude effective treatment.

Subject of Research: Animals

Article Title: Polyploidy reprograms epithelial cells for motility and phagocytosis via stress signaling

News Publication Date: 21-Apr-2026

Web References: http://dx.doi.org/10.1083/jcb.202507096

References: Zhou et al., 2026. Journal of Cell Biology

Image Credits: ©2026 Zhou et al. Originally published in Journal of Cell Biology

Keywords: Cancer, Cancer cell phenotypes, Polyploids, Cell biology

Riboflavin, an essential micronutrient that humans cannot synthesize, must be obtained through dietary sources such as dairy, eggs, meat, and green vegetables. Once absorbed, the vitamin is metabolized into active cofactors that protect cellular components from oxidative damage. While this protective function is beneficial for maintaining healthy cell integrity, the team at RVZ has demonstrated that the same mechanisms also shield malignant cells, enabling their survival under conditions that would typically induce cell death.

Ferroptosis differs fundamentally from other forms of programmed cell death like apoptosis or necrosis. It is triggered by an accumulation of iron-dependent lipid peroxides, which leads to catastrophic membrane damage and ultimately the demise of the affected cell. This process has emerged as a pivotal biological mechanism not only in cancer but also in various neurodegenerative diseases and tissue injuries. The central mystery has been understanding how cancer cells circumvent ferroptosis to persist and proliferate uncontrollably.

The study highlights the role of FSP1 (ferroptosis suppressor protein 1), a critical enzyme that mitigates ferroptosis by maintaining antioxidant defenses inside the cell. Riboflavin-derived cofactors are indispensable for the enzymatic functions of FSP1, meaning that vitamin B2 metabolism is directly linked to the cancer cell’s ability to dodge ferroptotic death. Using advanced genome editing tools and cellular models, the researchers observed that disrupting riboflavin metabolism sensitized cancer cells to ferroptosis, thereby undermining their survival advantage.

This finding suggests that targeting the riboflavin metabolic pathway might represent a novel and effective strategy to selectively induce ferroptosis in cancer cells without affecting normal cells. Despite this potential, a significant challenge remains: no specific inhibitors of the metabolic enzymes involved in vitamin B2 processing have yet been identified or developed for clinical use.

To overcome this barrier, the research team explored the use of roseoflavin, a naturally occurring analog of riboflavin produced by certain bacteria. Roseoflavin mimics vitamin B2 but can interfere with its metabolic functions. Laboratory experiments demonstrated that roseoflavin, even at low concentrations, could trigger ferroptosis in cancer cells. This exciting result provides proof of concept that metabolic inhibition of riboflavin-dependent pathways can be harnessed to provoke ferroptotic cell death selectively, thereby laying the groundwork for future cancer therapies based on ferroptosis induction.

Looking ahead, the researchers are focused on refining and developing more potent and selective inhibitors of the riboflavin metabolic machinery. These next-generation molecules will be evaluated in preclinical models to assess their therapeutic efficacy and safety profile. Such developments could mark a paradigm shift in oncological treatment, especially for tumors that have developed resistance to conventional therapies.

Professor José Pedro Friedmann Angeli, leader of the research group, emphasized the broader implications of their findings. “Ferroptosis is not just critical in cancer biology but is increasingly recognized as a contributing factor in diverse pathological conditions, including neurodegeneration, ischemia-reperfusion injury, and post-transplant tissue damage,” he explained. Thus, an improved understanding of how vitamin B2 metabolism influences ferroptosis could also have significant repercussions in treating a variety of diseases beyond oncology.

The mechanistic insights gained from this study underscore the complex interplay between micronutrient metabolism and cell death regulation, enriching our molecular understanding of tumor biology. This intersection of metabolism and cell fate decisions represents a fertile ground for discovering biomarkers that can predict response to ferroptosis-based therapies as well as for the development of combination treatments that sensitize tumors to iron-dependent oxidative stress.

The study’s funding was provided by the German Research Foundation’s priority programme SPP2306, dedicated to ferroptosis research from molecular basics to clinical applications. Additionally, significant support came from the DeciFerr project, led by Professor Friedmann Angeli and backed by the European Research Council through an ERC Consolidator Grant awarded in May 2024. This robust financial backing highlights the recognized importance and cutting-edge nature of the work in this emerging field.

While the immediate focus remains on exploiting the riboflavin-FSP1 axis to combat cancer, ongoing research may unlock further therapeutic windows for managing neurodegenerative diseases such as Alzheimer’s and Parkinson’s, where ferroptotic mechanisms contribute to neuronal loss. The possibility of modulating ferroptosis bi-directionally—either enhancing it to kill cancer cells or suppressing it to preserve vulnerable neurons—illustrates the transformative potential of understanding this metabolic pathway in unprecedented detail.

As research progresses, the discovery that a simple vitamin like B2, commonly taken for granted as a dietary supplement, is intricately woven into the fundamental processes governing cell death resistance challenges previous assumptions. It invites clinicians, biochemists, and pharmacologists alike to re-examine the role of metabolism in cancer and develop new therapeutic paradigms to improve patient outcomes worldwide.

Subject of Research: Cells
Article Title: Riboflavin metabolism shapes FSP1-driven ferroptosis resistance
News Publication Date: 13-Mar-2026
Web References: http://dx.doi.org/10.1038/s41556-025-01856-x
References: Skafar et al., Riboflavin metabolism shapes FSP1-driven ferroptosis resistance, Nature Cell Biology, 2026
Image Credits: University of Würzburg / Rudolf Virchow Centre
Keywords: vitamin B2, riboflavin metabolism, ferroptosis, cancer therapy, programmed cell death, FSP1, roseoflavin, oxidative stress, lipid peroxidation, cancer resistance, translational cell biology, ferroptosis inhibitor

Leukemia stem cells are a particularly elusive population, responsible for the persistence and relapse of AML after conventional treatments. The Lund team embarked on a comprehensive proteomic analysis of these stubborn cancerous cells, comparing their surface proteins against those found on normal blood stem cells. This meticulous comparison led to the identification of a unique surface protein, SLAMF6, which exhibited expression solely on leukemia stem cells, not on their healthy counterparts.

The discovery of SLAMF6’s exclusive presence on AML stem cells suggested it might be integral to the leukemia’s strategy for immune escape. Further functional experiments using CRISPR/Cas9 gene editing confirmed that SLAMF6 plays a pivotal role in subverting the immune system’s T cell response. By manipulating the gene encoding SLAMF6, the researchers demonstrated that AML cells rely heavily on this protein to avoid immune surveillance, allowing the cancer to grow unchecked.

Building upon these insights, the research team engineered a novel antibody designed to target and block SLAMF6. This antibody effectively disabled the protein’s immune-evading function. Laboratory tests using human cells and innovative mouse models infused with human AML cells revealed that the antibody treatment restored the immune system’s ability to detect and eliminate the cancerous cells. The results were nothing short of a biological breakthrough: akin to flipping a switch that reignites the immune response against the tumor.

The implications of these findings are profound. While immunotherapy has transformed the treatment landscape for many solid tumors, AML has remained resistant to these advances, partly due to the complex mechanisms cancer cells employ to dodge immune detection. The identification and successful targeting of SLAMF6 provide a mechanistic explanation for the limited success of prior immunotherapies in AML and underscore the importance of precision medicine approaches tailored to individual tumor profiles.

This study underlines an essential shift towards more personalized cancer therapy paradigms. By harnessing detailed molecular knowledge of a patient’s cancer, clinicians may soon be able to deploy targeted treatments that specifically undermine the tumor’s defenses without collateral damage to normal cells. Such strategies promise to reduce the harsh side effects associated with current AML treatments like intensive chemotherapy and stem cell transplantation.

The research was conducted using a blend of in vitro experiments and sophisticated in vivo models, including mice transplanted with human AML cells. These dual approaches ensured that the findings have relevance not only in a controlled laboratory setting but also in more complex living systems, bolstering confidence in the potential clinical applicability of the antibody therapy.

Recognizing the therapeutic potential of their discovery, the researchers have founded a spin-off company, Lead Biologics, tasked with advancing the antibody through preclinical development and into clinical trials. Their goal is to translate this scientific breakthrough into a viable treatment option for patients urgently needing alternatives to current, often toxic regimens.

Despite the excitement surrounding these findings, the researchers caution that extensive further work is necessary before this therapy can be deemed patient-ready. Clinical trials will need to rigorously assess safety, dosage, and efficacy in diverse patient populations. Yet, the study sets a new benchmark in AML research, defining a clear target that could finally enhance immunotherapy’s impact on this stubborn leukemia.

Funding for this innovative project came from an array of prestigious institutions, including the Swedish Childhood Cancer Fund, the Swedish Cancer Society, and the Knut and Alice Wallenberg Foundation. Collaboration across disciplines and institutions was critical, emphasizing the integrative approach required to tackle challenging cancers like AML.

The study’s publication in the esteemed journal Nature Cancer illustrates the high caliber and global relevance of this work. It adds to the rapidly expanding field of cancer immunotherapy, where the hunt for novel immune evasion mechanisms continues to drive therapeutic innovation.

In the broader context, this research highlights the power of targeting immune escape pathways to overcome cancer resistance. Each newly discovered mechanism like SLAMF6 offers hope that, one day, even the most aggressive and treatment-resistant cancers can be outmaneuvered by the patient’s own immune system. The future of oncology likely depends on these finely targeted approaches, augmenting immune function to achieve durable remissions and ultimately cures.

Subject of Research: Cells

Article Title: Aberrant expression of SLAMF6 constitutes a targetable immune escape mechanism in acute myeloid leukemia

News Publication Date: 3-Oct-2025

Web References: https://doi.org/10.1038/s43018-025-01054-6

Image Credits: Tove Smeds / Lund University

Keywords: Acute Myeloid Leukemia, AML, Immunotherapy, SLAMF6, Immune Escape, Antibody Therapy, Leukemia Stem Cells, CRISPR/Cas9, Cancer Immunology, Targeted Treatment, Preclinical Research, Immuno-Oncology

This correction, published in the prestigious journal Cell Death Discovery, reinforces the initial groundbreaking assertion that tRF-29-79MP9P9NH525 can act as a molecular sentinel, detecting and tempering malignant progression. Gastric cancer, ranked among the most lethal malignancies worldwide, presents an urgent demand for precise and reliable biomarkers. Traditional protein-coding gene markers have suffered limitations in sensitivity and specificity. Thus, the emergence of tRFs introduces an entirely novel paradigm, expanding the non-coding RNA universe and offering exquisite cellular regulatory potential.

At the molecular level, the nuanced interaction between tRF-29-79MP9P9NH525 and the KIF14/AKT pathway unravels a sophisticated regulatory network that tempers cellular proliferation and survival mechanisms. KIF14, a kinesin family motor protein, is implicated in cytokinesis and chromosome segregation, processes often deregulated in cancers, while AKT, a well-known serine/threonine kinase, acts as a central node in prosurvival signaling. The study elucidates how tRF-29-79MP9P9NH525 downregulates KIF14 expression, consequently dampening AKT phosphorylation states that are essential for oncogenic signaling.

Employing advanced transcriptomic analyses combined with functional assays, the researchers meticulously delineate the tumor suppressive mechanisms enacted by tRF-29-79MP9P9NH525. The RNA fragment achieves this via binding to specific mRNA targets or associated protein complexes, leading to post-transcriptional repression of KIF14. This repression cascades downstream, reducing AKT pathway activation, which in turn curtails cellular proliferation, migration, and invasion—hallmarks of aggressive gastric cancer phenotypes. These findings pivotally highlight how minute RNA fragments can exert outsized influence on cellular fate decisions.

Recent technological advancements, such as RNA sequencing and crosslinking immunoprecipitation, have been central to uncovering the dynamic landscape of tRFs. This correction clarifies earlier data points, providing refined quantification of tRF-29-79MP9P9NH525 expression profiles across gastric cancer cell lines and patient-derived samples. Notably, the corrected data underscore a robust inverse correlation between tRF expression and tumor stage, supporting the concept of tRF-29-79MP9P9NH525 as a potent tumor suppressor intrinsically linked with clinical outcomes.

The implications of these findings extend beyond diagnostics into therapeutic strategies. By harnessing the tumor-suppressing potential of tRF-29-79MP9P9NH525, novel RNA-based therapeutics could be engineered to restore or mimic its activity within the tumor microenvironment. Such precision medicine approaches could synergize with existing treatments, potentially overcoming resistance mechanisms often encountered in gastric cancer therapeutics. The corrected data invigorate hope for employing tRF-focused interventions, marking a significant leap in RNA therapeutics.

Moreover, the study expands the conceptual framework of non-coding RNAs operating as dynamic modulators of oncogenic signaling cascades rather than as mere passive players. The intricate regulatory interplay demonstrated between tRF-29-79MP9P9NH525, KIF14, and AKT provides a compelling example of RNA’s expanding role in cancer biology, inaugurated by small RNA species that can decisively reprogram malignant cellular behavior via specific molecular interactions. This dynamic challenges the dogmatic protein-centric view of cellular regulation.

In addition to biological significance, the correction emphasizes the technical rigor involved in validating tRF-mediated pathways. The use of CRISPR-Cas9 gene editing to manipulate tRF-29-79MP9P9NH525 expression, coupled with phosphoproteomic profiling, validates causality over correlation. This methodological sophistication strengthens the impact and reproducibility of the study’s conclusions, setting a new benchmark in non-coding RNA research within oncology.

The corrected findings also bring to light the potential use of tRF-29-79MP9P9NH525 as an early detection biomarker. The study illustrates that serum levels of this tRF can be quantifiably measured through liquid biopsy platforms, offering a minimally invasive means to assess gastric cancer progression. Such early diagnostic tools are critical to improving patient survival rates by enabling timely interventions before the disease advances to metastatic or drug-resistant stages.

An intriguing aspect disclosed in the correction pertains to the evolutionary conservation of tRF-29-79MP9P9NH525 sequences across mammalian species, suggesting a fundamental and possibly ancient role in maintaining cellular homeostasis. This evolutionary perspective provides an additional layer of understanding, revealing how such small RNA fragments have been co-opted through natural selection to regulate vital cellular processes including proliferation, apoptosis, and stress responses—processes often dysregulated in cancer.

Furthermore, the correction highlights collaborative endeavors integrating multi-omics datasets. By combining genomics, transcriptomics, and proteomics analyses, the researchers paint an all-encompassing picture of the molecular interplay modulated by tRF-29-79MP9P9NH525. These integrative approaches are essential to decode the complex biological networks involved in tumor suppression, and to identify novel intervention points that could be exploited therapeutically.

Despite the promising advances, this correction calls for further exploration into the biogenesis pathways of tRF-29-79MP9P9NH525 within gastric epithelial cells and the tumor microenvironment. Elucidating the enzymatic machineries responsible for its generation, stability, and degradation can illuminate additional regulatory checkpoints, and potentially reveal targets for modulating its levels in cancerous tissues.

Another dimension broached by the correction is the potential cross-talk between tRF-29-79MP9P9NH525 and other non-coding RNA species such as microRNAs and long non-coding RNAs, forming expansive regulatory networks that orchestrate gene expression programs. Deciphering such networks is crucial to understanding the systems-level regulation driving tumor suppression and cancer progression.

Clinically, the correction reiterates the challenges of translating tRF-based findings into routine practice, emphasizing the need for comprehensive clinical trials to authenticate biomarker utility and therapeutic efficacy. Patient stratification based on tRF-29-79MP9P9NH525 expression levels could refine treatment regimens, paving the way for personalized medicine in gastric cancer care.

In summary, this pivotal correction not only reinforces the critical role of tRF-29-79MP9P9NH525 as both a biomarker and tumor suppressor but also advances the broader field of RNA biology by illuminating novel mechanistic pathways governing gastric cancer progression. It spotlights the transformative potential of tRFs in oncological research and clinical practice, signaling a paradigm shift that may revolutionize early detection, prognostication, and targeted therapies in oncology.

As scientific inquiry continues to unravel the complexities of cancer biology, the emergence of small non-coding RNAs such as tRF-29-79MP9P9NH525 exemplifies the exciting nexus between molecular innovation and clinical impact. This correction stands as a testament to the dynamic nature of research—where refinement and rigor propel us closer to defeating one of humanity’s most formidable diseases.

Subject of Research: Identification of tRF-29-79MP9P9NH525 as a biomarker and tumor suppressor in gastric cancer through its regulation of the KIF14/AKT pathway.

Article Title: Correction to: Identification of tRF-29-79MP9P9NH525 as a biomarker and tumor suppressor of gastric cancer via regulating KIF14/AKT pathway.

Article References:
Ge, J., Dai, J., Ji, H. et al. Correction to: Identification of tRF-29-79MP9P9NH525 as a biomarker and tumor suppressor of gastric cancer via regulating KIF14/AKT pathway. Cell Death Discov. 11, 353 (2025). https://doi.org/10.1038/s41420-025-02614-6

Image Credits: AI Generated